Healio Psoriatic Disease Current Issue
The following articles appeared in the print edition of Healio Psoriatic Disease.
Table of Contents
- Looking Forward: Maximizing Efficiency From Electronic Health Records Rebecca L. Forand
-
- Baseline radiographic damage prevalence ‘substantial’ in psoriatic arthritis Erich Martin
- COVID-19 pandemic ‘still with us’ for patients with autoimmune, inflammatory diseases Rob Volansky
- From ‘gratitude tax’ to ‘workplace tribalism’: Combating institutional racism in academia Rob Volansky; Puja Mehta, MD
- Guselkumab’s safety profile consistent regardless of TNF-inhibitor use in psoriatic arthritis Erich Martin
- Patients’ priorities, individual burden should guide psoriatic arthritis treatment Erich Martin
- Q&A: Patients with skin of color experience disparities in dermatology treatment Kate Young; Kassahun Bilcha, MD, FAAD
- Ustekinumab, TNF inhibitors exhibit comparable 3-year persistence in psoriatic arthritis Erich Martin
- Vaccination reduces risk for severe COVID-19 in patients using rituximab Hunter Firment
-
- Halobetasol, tazarotene lotion efficacious in palmoplantar psoriasis Rebecca L. Forand
- PCSK9 may be ‘implicated’ in psoriasis risk Rob Volansky
- Spesolimab may control generalized pustular psoriasis flares within 24 hours Gabrielle M. Grasso
- CAL/BDP cream efficacious in plaque psoriasis treatment for patients with skin of color Rebecca L. Forand
- Speaker: ‘Localized psoriasis is still important psoriasis’ Rebecca L. Forand